Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma
Authors:
Open Access
- 29 May 2013
- journal article
- Published by Spandidos Publications in Oncology Letters
- Vol. 6 (2) , 375-380
Abstract
The Trop‑2 gene has been examined in various carcinomas and is reported to be significantly associated with prognosis. Little is known with regard to Trop‑2 gene expression in advanced non‑small cell lung carcinoma (NSCLC). The present study investigated the expression of Trop‑2 and its association with the prognosis of advanced NSCLC. The clinical records of 87 patients with advanced NSCLC, consisting of 37 cases of squamous cell carcinoma (SCC) and 50 cases of adenocarcinoma (AdC), together with 17 tumor‑adjacent normal tissues, were retrospectively evaluated. Trop‑2 expression was measured using an immunohistochemical method and its association with clinicopathological data and prognosis was also evaluated. The expression of Trop‑2 was significantly higher in the cancer tissues compared with the tumor‑adjacent normal tissues, and significantly higher in SCC compared with AdC (P=0.018). In SCC, the overexpression of Trop‑2 was only correlated with the histological grade of the tumor (P=0.035) and no correlation was observed with gender, age, lymph node metastasis, TNM stage or Eastern Cooperative Oncology Group (ECOG) performance status (PS). In AdC, the overexpression of Trop‑2 was correlated with the histological grade, lymph node metastasis and TNM stage (P=0.01, 0.024 and 0.015, respectively), while no correlation with gender, age or ECOG‑PS was observed. The survival frequency was significantly higher in the Trop‑2‑negative patients compared with the Trop‑2‑positive patients [17.25 months (95% CI, 14.922‑19.577) vs. 13.274 months (95% CI, 11.507‑15.041); P=0.008]. The survival time was significantly longer in the Trop‑2‑negative AdC patients [17.275 months (95% CI, 14.575‑19.975) vs. 11.469 months (95% CI, 11.507‑15.041); P=0.002], but not in the SCC patients [17.167 months (95% CI, 12.428‑21.906) vs. 14.647 months (95% CI, 12.062‑17.232); P=0.276]. The multivariate analysis revealed that Trop‑2 expression [hazard ratio (HR) 2.381; P=0.038], TNM stage (HR, 2.193; P=0.03) and ECOG‑PS (HR, 2.696; P=0.007) were independent predictors for the survival outcome of patients with AdC. These results suggest that Trop‑2 overexpression is closely correlated with an unfavorable prognosis in advanced NSCLC. Trop‑2 is an independent prognostic marker and a potential new therapeutic target in advanced AdC.Keywords
This publication has 15 references indexed in Scilit:
- Significance of EpCAM and TROP2 expression in non-small cell lung cancerWorld Journal of Surgical Oncology, 2012
- Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathwayMolecular Cancer, 2010
- High expression of TROP2 correlates with poor prognosis in pancreatic cancerBritish Journal of Cancer, 2008
- Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancersMolecular Cancer Therapeutics, 2008
- TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavityLaboratory Investigation, 2008
- Two novel mutations identified in two Chinese gelatinous drop-like corneal dystrophy families2007
- A novel TACSTD2 gene mutation in a Turkish family with a gelatinous drop-like corneal dystrophy.2006
- Clinical Significance ofTROP2Expression in Colorectal CancerClinical Cancer Research, 2006
- Short Term Cyclin D1 Overexpression Induces Centrosome Amplification, Mitotic Spindle Abnormalities, and AneuploidyJournal of Biological Chemistry, 2005
- Assignment1 of TACSTD1 (alias TROP1, M4S1) to human chromosome 2p21 and refinement of mapping of TACSTD2 (alias TROP2, M1S1) to human chromosome 1p32 by in situ hybridizationCytogenetic and Genome Research, 2001